New statin use and left ventricular structure: Estimating long‐term associations in the Multi‐Ethnic Study of Atherosclerosis (<scp>MESA</scp>)

Strand, Lauren; Young, Rebekah; Bertoni, Alain G.; Bluemke, David A.; Burke, Gregory L.; Lima, João A.C.; Sotoodehnia, Nona; Psaty, Bruce M.; McClelland, Robyn L.; Heckbert, Susan R.; Delaney, Joseph A.

doi:10.1002/pds.4389

Cited by 3 publications

(2 citation statements)

References 70 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also in patients with non-ischaemic heart failure, atorvastatin treatment was associated with improvement in LV ejection fraction and LV chamber size [ 12 ], while another study in patients with hypertrophic cardiomyopathy demonstrated no effect of atorvastatin on reduction of LV mass [ 13 ]. Over 10 years of follow-up in 2389 participants free of established CVD from the Multi-Ethnic study of Atherosclerosis, a very modest association between statin use and less increase in LV mass assessed by cardiac magnetic resonance imaging was found [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Preclinical cardiac organ damage during statin treatment in patients with inflammatory joint diseases: the RORA-AS statin intervention study

Rollefstad

Gerdts

et al. 2020

Rheumatology

View full text Add to dashboard Cite

Objective Statin treatment has been associated with reduction in blood pressure and arterial stiffness in patients with inflammatory joint diseases (IJD). We tested whether statin treatment also was associated with regression of preclinical cardiac organ damage in IJD patients. Methods Echocardiography was performed in 84 IJD patients (52 RA, 20 ankylosing spondylitis, 12 psoriatric arthritis, mean age 61 (9) years, 63% women) without known cardiovascular disease before and after 18 months of rosuvastatin treatment. Preclinical cardiac organ damage was identified by echocardiography as presence of left ventricular (LV) hypertrophy, LV concentric geometry, increased LV chamber size and/or dilated left atrium. Results At baseline, hypertension was present in 63%, and 36% used biologic DMARDs (bDMARDs). Preclinical cardiac organ damage was not influenced by rosuvastatin treatment (44% at baseline vs 50% at follow-up, P = 0.42). In uni- and multivariable logistic regression analyses, risk of preclinical cardiac organ damage at follow-up was increased by higher baseline body mass index [odds ratio (OR) 1.3, 95% CI: 1.1, 1.5, P = 0.01] and presence of preclinical cardiac organ damage at baseline (OR 6.4, 95% CI: 2.2, 18.5, P = 0.001) and reduced by use of bDMARDs at follow-up (OR 0.3, 95% CI: 0.1, 0.9, P = 0.03). Conclusion Rosuvastatin treatment was not associated with a reduction in preclinical cardiac organ damage in IJD patients after 18 months of treatment. However, use of bDMARDS at follow-up was associated with lower risk of preclinical cardiac organ damage at study end, pointing to a possible protective cardiac effect of bDMARDs in IJD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Preclinical cardiac organ damage during statin treatment in patients with inflammatory joint diseases: the RORA-AS statin intervention study

Rollefstad

Gerdts

et al. 2020

Rheumatology

View full text Add to dashboard Cite

show abstract

“…One MESA study examined the association between H2 receptor antagonists and changes in LV morphology [51], a relationship that had previously mostly only been studied in animal models. Another MESA study looked at new statin use and cardiac remodeling [52] and a UK Biobank study evaluated the impact of menopausal hormone therapy (MHT) in post-menopausal women free of CVD [53]. Compared to non-users, H2 receptor antagonist users had fewer detrimental changes in LV parameters.…”

Section: Associations With LV Structure and Functionmentioning

confidence: 99%

Advances in population-based imaging using cardiac magnetic resonance

Beyer

Petersen

2019

Prog. Biomed. Eng.

View full text Add to dashboard Cite

Large population-based studies have helped to identify cardiovascular risk factors and to understand the natural progression of diseases. Cardiac magnetic resonance (CMR) is the reference method for the assessment of ventricular morphology and function given the low variance between scans. In addition, advanced sequences such as MR tagging, T1 mapping, and late gadolinium enhancement allow to assess regional ventricular function and fibrotic changes. MESA was the first study to use CMR on a large scale in a sample of the general population. Subsequent studies focused on cohorts of particular ethnicities or from certain locations with the Jackson Heart Study looking at African-Americans and the Dallas Heart Study at Dallas County Residents. More recently, the German National Cohort and UK Biobank have started to perform CMRs in a significantly larger number of participants (30,000 and 100,000, respectively). The introduction of CMR into prospective cohort studies has allowed to characterize ventricular remodeling in individuals of different age, sex, and gender and has found associations with new environmental exposures. The ability to detect subclinical changes in asymptomatic individuals has also been highlighted by reports of a high number of missed myocardial infarctions (MI) using CMR. In this review, we discuss the use of CMR in the different large population-based studies and compare the various associations found with left and right ventricular structure and function. In addition, we outline automated image analysis strategies aimed at overcoming challenges posed by the large amount of data in population-based studies.

show abstract

Statins for Cardiac and Vascular Protection During and After Cancer Therapy

Heiston

Hundley

2022

Curr Oncol Rep

View full text Add to dashboard Cite

New statin use and left ventricular structure: Estimating long‐term associations in the Multi‐Ethnic Study of Atherosclerosis (MESA)

Abstract: In contrast to previous small studies, we found very modest associations between statin use and indices of left ventricular remodeling over 10 years in this prospective study of a diverse cohort.

Cited by 3 publications

References 70 publications

Preclinical cardiac organ damage during statin treatment in patients with inflammatory joint diseases: the RORA-AS statin intervention study

Preclinical cardiac organ damage during statin treatment in patients with inflammatory joint diseases: the RORA-AS statin intervention study

Advances in population-based imaging using cardiac magnetic resonance

Statins for Cardiac and Vascular Protection During and After Cancer Therapy

Contact Info

Product

Resources

About